Eleven Biotherapeutics

Press Releases
 
Press Releases
Date Title and Summary View
April 2, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced new preclinical data with VB4-845, the active pharmaceutical ...
March 27, 2017 Single-agent and Combination Data Support Clinical Development Plan CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs)...
March 24, 2017 -- Advancing Late-Stage Targeted Protein Therapeutics Pipeline for Treatment of Cancers with High Unmet Medical Need -- -- Completed Integration of Viventia Bio -- -- Topline Phase 3 Data for Lead Drug Candidate Vicinium™, in Development for Non-Muscle Invasive Bladder Cancer...
March 22, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that it will host a live conference call and webcast at 8:00 ...
March 20, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive Officer, ...
March 1, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that Stephen HurlPy, President and Chief Executive Officer, ...
February 7, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive Officer, ...
November 14, 2016 -Management to host conference call today at 8:30 a.m. ET- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform...
November 4, 2016 -Conference call scheduled for November 14, 2016 at 8:30 a.m. ET- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late stage clinical oncology company advancing a broad pipeline of novel product candidates based on a Targeting Protein Therapeutics (TPTs) pl...
September 21, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), today reported that in connection with the appointment of each of Stephen Hurly as President and Chief Executive Officer, Arthur P. DeCillis, M.D., as Chief Medical Officer, Glen MacDonald, Ph.D., as Chief Scientific Officer...
1
... NextLast
Add to Briefcase = add release to Briefcase
NASDAQ: EBIO
Price:
1.92
Change:
0.00
Day High:
1.96
Day Low:
1.90
Volume:
89,430
4:00 PM ET on April 26, 2017
Delayed at least 20 minutes.